Trial composition
0 of 0 selected trial records include at least one phase value; 0 of 0 include a status value in the retained structured contract.
Not FDA-approved1,3Evidence: Animal and lab onlyNot a peptideMetabolic and weight
Also called 5-Amino-1-methylquinolinium1
Not a peptide: a small molecule often looked up alongside peptides.
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small synthetic compound, not a peptide. Researchers made it to block NNMT, an enzyme involved in how fat cells use energy.1,2 Its published evidence is laboratory and mouse research: in an 11-day study, obese mice given it lost weight and fat mass.2 No study in people and no FDA approval are reported in the sources reviewed here, and it is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.2,3,5
| Substance type | Not a peptide. FDA’s substance registry records 5-amino-1-methylquinolinium as a chemical compound, and the 2018 study that tested it describes it as a small molecule inhibitor of the enzyme NNMT.1,2 |
|---|---|
| What it is | A small quinolinium compound that inhibits the enzyme nicotinamide N-methyltransferase (NNMT), recorded by FDA’s substance registry as 5-amino-1-methylquinolinium.1,2 |
| FDA status | No FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page does not list it.1,3 |
| Human evidence | None found in the sources reviewed here: the 2018 study that introduced it tested cells and mice.2 |
| Evidence strength | Animal and lab studies only. The cited sources report no completed human study; the research base consists of animal, cell, or other laboratory work. How this label is assigned |
5-Amino-1MQ is a synthetic chemical compound, not a peptide. FDA’s substance registry records it as 5-amino-1-methylquinolinium, a charged quinolinium ion.1
It is one of a series of methylquinolinium compounds that researchers described in 2018 as small molecule inhibitors of nicotinamide N-methyltransferase (NNMT).2
NNMT is an enzyme in fat cells and other tissues that plays a part in cellular energy use. In fat cells grown in the laboratory, NNMT inhibitors raised levels of NAD+ and S-adenosylmethionine and reduced fat formation, according to the 2018 study.2
The study reported that the compounds did not block several related enzymes it tested.2
None of the sources reviewed here describes a study of 5-Amino-1MQ in people.1,2
In the 2018 study, mice made obese by a high-fat diet lost weight over 11 days of treatment and had less white fat and lower cholesterol, while untreated mice gained slightly. The treated mice did not eat less.2
Evidence-strength label: Animal and lab studies only. How this label is assigned
None of the sources reviewed here reports an approval of 5-Amino-1MQ by FDA.1,3
FDA’s compounding safety-risk page, current as of April 22, 2026, does not list 5-Amino-1MQ.3
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. 5-Amino-1MQ is not among them.4,5
Whether it has any effect in people, and whether it is safe for people: the sources reviewed here report only cell and mouse research.2
Whether the short-term weight loss seen in mice lasts, since the study treated them for 11 days.2
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for 5-Amino-1MQ: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for 5-Amino-1MQ are a bounded selection, not every registration or paper about 5-Amino-1MQ. For the years before 5-Amino-1MQ was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list 5-Amino-1MQ as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name 5-Amino-1MQ in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
This profile has no living status brief. Inspect the cited profile records below.
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
0 of 0 selected trial records include at least one phase value; 0 of 0 include a status value in the retained structured contract.
0 of 0 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
Citations
Numbered markers in the text point here. Each link opens the original public record.
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
Biochemical Pharmacology · Official source · Source checked November 16, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026